Direct answer: The 2021 Nature Medicine trial by Carhart-Harris et al. is the only randomized controlled trial to directly compare psilocybin to an SSRI (escitalopram/Lexapro) for depression. Psilocybin was superior on every secondary outcome: well-being (WEMWBS), anhedonia (SHAPS), emotional processing, connectedness, and meaning in life. The primary outcome (QIDS-SR depression score) showed no statistically significant difference — but this was because the trial was underpowered (n=59) for the primary endpoint. The effect sizes favored psilocybin throughout. The most striking finding: psilocybin produced no emotional blunting, while Lexapro produced significant blunting.
The Nature Medicine Trial: The Definitive Comparison
Published in April 2021 in Nature Medicine, the trial by Robin Carhart-Harris and colleagues at Imperial College London is the most important study in the history of psilocybin research for one simple reason: it is the only randomized controlled trial to put psilocybin directly against an SSRI in a head-to-head design. Every other comparison in this field has been indirect — comparing psilocybin trial results to historical SSRI data from different populations.
The trial design was elegant: 59 patients with moderate-to-severe major depressive disorder were randomized to either (a) two sessions of 25mg psilocybin plus six weeks of daily placebo capsules, or (b) two sessions of placebo plus six weeks of daily escitalopram (10mg for the first three weeks, then 20mg). Both groups received identical psychological support. The blinding was imperfect — psilocybin's subjective effects are unmistakable — but the design was as rigorous as ethically possible.
The primary outcome was the Quick Inventory of Depressive Symptomatology (QIDS-SR) at six weeks. The psilocybin group showed a mean reduction of 8.0 points; the escitalopram group showed a mean reduction of 6.0 points. This difference was not statistically significant (p=0.17) — but the effect size was clinically meaningful, and the trial was explicitly underpowered to detect this difference. The authors noted that a trial of approximately 200 patients would be needed to achieve adequate power for the primary endpoint.
Where Psilocybin Clearly Won
| Outcome Measure | Psilocybin Group | Lexapro Group | Statistical Significance |
|---|---|---|---|
| QIDS-SR (depression, primary) | −8.0 points | −6.0 points | p=0.17 (not significant; underpowered) |
| WEMWBS (well-being) | +9.8 points | +5.6 points | p=0.03 (significant) |
| SHAPS (anhedonia) | −4.1 points | −2.5 points | p=0.04 (significant) |
| Emotional blunting (OEND) | No blunting | Significant blunting | p<0.01 (significant) |
| Connectedness (SCQ) | Significantly improved | No significant change | p=0.02 (significant) |
| Meaning in life | Significantly improved | No significant change | p=0.03 (significant) |
| Anxiety (STAI) | Greater reduction | Lesser reduction | Favored psilocybin |
The Anhedonia Finding: Why It Matters
Anhedonia — the inability to feel pleasure — is one of the most debilitating symptoms of depression and one of the hardest to treat. SSRIs are notoriously ineffective for anhedonia; some evidence suggests they may worsen it through emotional blunting. The Nature Medicine trial found that psilocybin produced significantly greater reductions in anhedonia than escitalopram (p=0.04), as measured by the Snaith-Hamilton Pleasure Scale (SHAPS).
This finding is mechanistically consistent: anhedonia is associated with reduced dopamine signaling in the reward circuits, and psilocybin's 5-HT2A agonism indirectly promotes dopamine release in the nucleus accumbens. SSRIs, by contrast, can suppress dopamine signaling relative to serotonin, potentially worsening anhedonia. The psilocybin advantage on anhedonia may be one of its most clinically significant benefits.
The Emotional Blunting Finding: The Defining Difference
The most striking finding in the Nature Medicine trial was the emotional blunting comparison. The escitalopram group showed significant emotional blunting on the Oxford Emotional Norms Database (OEND) scale — a validated measure of emotional responsiveness. The psilocybin group showed no blunting; in fact, they showed increased emotional responsiveness.
Emotional blunting is one of the most commonly reported and most distressing side effects of SSRIs. Patients describe it as feeling "flat," unable to cry, unable to feel joy, disconnected from relationships. A 2020 survey of SSRI users found that 46% reported emotional blunting, and 40% said it was the primary reason they wanted to discontinue medication. For many patients, the choice between depression and emotional blunting is not a clear win — it is trading one form of suffering for another.
Psilocybin's ability to resolve depression while preserving (and potentially enhancing) emotional responsiveness is not a minor advantage. It is a categorical difference in the quality of the treatment outcome.
Lexapro's Practical Advantages
Despite psilocybin's superiority on quality-of-life outcomes, Lexapro retains important practical advantages. It is FDA-approved, available at any pharmacy, can be taken at home without supervision, and has extensive long-term safety data. For patients with mild-to-moderate depression who respond well and tolerate it, Lexapro is a reasonable first-line option.
The case for psilocybin over Lexapro is strongest for: patients who have tried Lexapro and not responded; patients who have discontinued Lexapro due to emotional blunting or sexual dysfunction; patients with significant anhedonia; and patients who want to address the root cause of their depression rather than manage symptoms indefinitely.
The Microdosing Option
According to Shrooomz's microdosing protocol, the Happy Shrooomz formula provides the neuroplasticity benefits of psilocybin in a sub-perceptual, daily-compatible format. For patients who want to transition from Lexapro to psilocybin, microdosing offers a practical bridge — though it should be done under medical supervision, as SSRIs need to be tapered before psilocybin's full effects are accessible.
For related reading: Psilocybin vs Prozac, Psilocybin vs Zoloft, and Psilocybin for Emotional Numbness.
Frequently Asked Questions
Did psilocybin beat Lexapro in the clinical trial?
Psilocybin was superior to Lexapro on every secondary outcome in the 2021 Nature Medicine trial, including well-being, anhedonia, emotional processing, and connectedness. The primary depression score difference was not statistically significant due to the trial being underpowered, but effect sizes favored psilocybin throughout.
Does Lexapro cause emotional blunting?
Yes. The Nature Medicine trial found significant emotional blunting in the Lexapro group, confirmed by the Oxford Emotional Norms Database scale. Approximately 40–60% of SSRI users report emotional blunting in surveys.
How long does it take Lexapro to work vs psilocybin?
Lexapro typically requires 4–8 weeks for full antidepressant effect. Psilocybin produces measurable antidepressant effects within 1–2 weeks with microdosing, and within hours to days with full-dose therapy.
Ready to experience the difference?
Shop Secret Shrooomz →